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Background-—Outpatient ascertainment of peripheral artery disease (PAD) is rarely considered in the measurement of PAD clinical
burden; therefore, the clinical burden of PAD likely has been underestimated while contributing to a decreased awareness of PAD
in comparison to other circulatory system disorders.
Methods and Results-—The purpose of this study was to estimate the age-standardized annual period prevalence and incidence of
PAD in the outpatient and inpatient settings using data from the Atherosclerosis Risk in Communities (ARIC) study linked with
Centers for Medicare and Medicaid Services claims. The majority (>70%) of all PAD encounters occurred in the outpatient setting.
The weighted mean age-standardized prevalence and incidence of outpatient PAD was 11.8% (95% CI 11.5–12.1) and 22.4 per
1000 person-years (95% CI 20.8–24.0), respectively. Black patients had higher weighted mean age-standardized prevalence
(15.6%; 95% CI 14.6–16.4) compared with white patients (11.4%; 95% CI 11.1–11.7). Black women had the highest weighted mean
age-standardized prevalence (16.9%; 95% CI 16.0–17.8). Black patients also had a higher incidence rate of PAD (31.3 per
1000 person-years; 95% CI 27.3–35.4) compared with white patients (25.4 per 1000 person-years; 95% CI 23.5–27.3). PAD
prevalence and incidence did not differ by sex alone.
Conclusions-—This study provides comprehensive estimates of PAD in the inpatient and outpatient settings where the majority of
PAD burden was found. PAD is an important circulatory system disorder similar in prevalence to stroke and coronary heart
disease. ( J Am Heart Assoc. 2017;6:e003796. DOI: 10.1161/JAHA.116.003796.)
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P eripheral artery disease (PAD) is a progressiveatherosclerotic disorder that can lead to poor quality of
life,1 an increased risk of hospitalization and limb amputa-
tion,2 high mortality,3 and high costs of care.4 Early PAD
detection in the outpatient setting combined with ambulatory
follow-up care could help slow disease progression and
reduce PAD-related hospitalizations and sequelae.5 However,
the extent to which PAD is managed in the outpatient setting
is not well documented.
Reported estimates of clinical PAD prevalence and inci-
dence tend to focus on only hospitalized cases.6–12 Estimates
of disease occurrence in both inpatient and outpatient
settings could provide a broader, more comprehensive
understanding of PAD and could lead to improved resource
From the Department of Surgery, School of Medicine (C.A.K.), Department of Epidemiology, Gillings School of Global Public Health (A.K.-N., J.L.L., G.H., L.L.), and Cecil
G. Sheps Center for Health Services Research (A.K.-N.), The University of North Carolina at Chapel Hill, NC; Center for Preventive Medicine, Duke Clinical Research
Institute, Durham, NC (L.W.); Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (E.S., K.M.); Health Economics
and Outcomes Research, Life Sciences Optum, Eden Prairie, MN (L.G.S.B.).
Accompanying Tables S1 through S6 and Figure S1 are available at http://jaha.ahajournals.org/content/6/5/e003796/DC1/embed/inline-supplementary-material-1.
pdf
Correspondence to: Corey A. Kalbaugh, PhD, MS, 3024 Burnett-Womack Bldg, CB 7212, Chapel Hill, NC 27599-7212. E-mail: corey_kalbaugh@med.unc.edu
Received August 25, 2016; accepted January 17, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
DOI: 10.1161/JAHA.116.003796 Journal of the American Heart Association 1
ORIGINAL RESEARCH
allocation to prevent PAD-related complications. Administra-
tive claims data capture comprehensive services across the
spectrum of health care settings and provide an opportunity
for a more inclusive assessment of PAD burden.
We estimated the age-standardized annual period preva-
lence and incidence of PAD in the inpatient and outpatient
setting over a 10-year period (2003–2012) using data from
the biracial Atherosclerosis Risk in Communities (ARIC) study
cohort13 linked with the Centers for Medicare and Medicaid
Services (CMS) claims information for Medicare fee-for-
service (FFS) beneficiaries aged ≥65 years. To further inform
prevention efforts, we examined differences in estimates of
annual PAD period prevalence and incidence across strata of
age, sex, and race.
Methods
Study Population
The ARIC cohort study
The biracial ARIC cohort, established to examine the etiology
of atherosclerosis and its clinical manifestations, includes
15 792 participants (aged 45–64 years at baseline) enrolled
between 1987 and 1989. The ARIC cohort was selected by
probability sampling from 4 US communities: Washington
County, Maryland; Forsyth County, North Carolina; the city of
Jackson, Mississippi; and the suburbs of Minneapolis, Min-
nesota.13 ARIC participants enrolled continuously for at least
1 year in Medicare Parts A and B through an FFS plan from
2003 to 2012 were eligible for inclusion. Data were collected
on cohort participants at 5 clinic examinations and through
annual follow-up telephone interviews.
Linkage of ARIC cohort data with CMS claims
An interagency agreement between the National Heart, Lung,
and Blood Institute and CMS has enabled Medicare claims
information to be obtained for the 14 899 ARIC cohort
participants who were Medicare eligible between the years
1991 and 2012. Data for ARIC cohort participants were linked
with CMS claims data, matching on participants’ social
security numbers, sex, and date of birth. Of the 14 899
Medicare-eligible participants, 14 702 ARIC cohort identifiers
(98.7%) were matched successfully.
Participant information on enrollment in Medicare FFS was
obtained from monthly enrollment indicators for Part A, Part
B, and Medicare Advantage buy-in available through annual
CMS Medicare beneficiary summary files. Continuous enroll-
ment periods were created to indicate uninterrupted CMS
Medicare FFS coverage, defined as enrollment in CMS
Medicare Part A and Part B and lack of enrollment in a
Medicare Advantage plan. Participants contributed data to
calendar years in which they had uninterrupted FFS coverage.
Participants were excluded if they had continuous Medicare
Advantage enrollment or gaps in FFS coverage because of (1)
missing enrollment information, (2) discontinuation of enroll-
ment, or (3) enrollment in a Medicare Advantage plan at any
month in the observation year. Participants aged <65 years
and those of a race other than black or white were also
excluded (see Table S1). For those with multiple enrollments
periods, the longest enrollment period was selected to give
the best opportunity to capture relevant claims. The enroll-
ment period selected was the first enrollment period for
10 144 participants (97%). The final analytic sample included
10 481 ARIC participants with 67 492 person-years of FFS
enrollment time.
Demographics and comorbidities
Demographic information on age (at beginning of enrollment
year), race, and sex was obtained from annual Medicare
beneficiary summary files. Age was categorized as 65 to
74 years of age and ≥75 years of age. The Klabunde
adaptation of the Charlson Comorbidity Index was used to
identify comorbidity burden using claims from the inpatient
and outpatient settings.14,15 All claims present in each
calendar year (prior to a PAD case) were used to calculate
an annual Charlson Comorbidity Index score.
Ascertainment of PAD
PAD-related outpatient office visits, outpatient diagnostic
tests, inpatient visits, and procedures were identified from the
MedPAR (Medicare Provider Analysis and Review) records and
the Carrier and Outpatient claims files using codes from the
International Classification of Diseases, Ninth Revision (ICD);
Current Procedural Terminology, 4th edition (CPT); Healthcare
Common Procedure Coding System (HCPCS); and Federally
Qualified Healthcare Center (FQHC) (Table S2). Codes used in
the present study were adapted from previous PAD-related
administrative studies.16,17
Prevalence of PAD
Annual PAD period prevalence was estimated for 2003 to
2012 using information on any PAD encounters in the
inpatient and outpatient settings, including both prevalence
cases from prior years and new incident cases during the year
of observation. Overall mean annual prevalence, weighted to
reflect the distribution of cases across all years, was also
estimated. The denominator for annual period prevalence
estimates included cohort participants alive at the beginning
of the year with continuous enrollment in FFS for the entire
year of observation or until death. For each year of
observation, prevalent inpatient PAD was defined as ≥1
hospitalization with a PAD code in any of the 25 diagnosis or
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procedure positions; prevalent outpatient PAD was defined as
≥1 claim with PAD diagnosis or procedure codes in any of the
12 diagnosis positions or 6 procedure positions. A sensitivity
analysis using ≥2 outpatient claims was conducted to address
the possibility of rule-out diagnoses (Table S3).
Incidence of PAD
A 2-year look back period was chosen to minimize misclas-
sification of prevalent events as incident events18; therefore,
the shortest enrollment window of ARIC participants was
>24 months. ARIC participants with a prevalent PAD-related
inpatient or outpatient code occurring any time within 2 years
of the year in question were excluded from annual incidence
analyses. Annual incidence rates are presented for the years
2005 to 2012. Overall mean incidence, weighted to reflect the
distribution of events across all years, was also estimated.
The denominator for annual incidence estimates included
cohort participants’ time at risk in continuous enrollment
during the year of observation or until death if it occurred
during the year of observation.
Annual inpatient PAD incidence was defined as ≥1
hospitalization with a PAD-related ICD diagnosis or procedure
code during each year of observation. Annual outpatient PAD
incidence was defined as ≥2 claims within 12 consecutive
months with a PAD-related ICD, CPT, HCPCS, or FQHC code;
the claims had to occur ≥1 day apart, and the incident date
was defined as the date of the second claim. If a singular
outpatient encounter preceded an inpatient encounter within
365 days, the incident date was the inpatient date of
discharge. Singular outpatient encounters occurring with no
hospitalizations or outpatient encounters within 365 days
were not considered incident PAD. This definition of incidence
was chosen to reduce the misclassification of rule-out
diagnoses resulting from a singular encounter in the outpa-
tient setting.19 Each individual contributed between 1 and
12 months to each yearly estimate of incidence. Time
contributed to the study for each ARIC participant was
converted to and reported in person-years.
Statistical Analysis
Direct standardization was used to estimate age-standardized
overall and annual prevalence of PAD with 95% CIs from 2003
to 2012. Direct standardization was used to estimate age-
standardized overall and annual incidence of PAD (per
1000 person-years) with 95% CI from 2005 to 2012. Preva-
lence estimates were age-standardized to reflect the age,
race, and sex distribution of the 2005 Medicare population
aged ≥65 years. Age categories for standardization of preva-
lence estimates included 65 to 69, 70 to 74, 75 to 79, and
≥80 years of age. Incidence estimates were age-standardized
to reflect the age, race, and sex distribution of the 2005
Medicare population aged ≥67 years, given a 2-year look-
back period for excluding prevalence cases. Estimates were
calculated overall; by health care setting (inpatient versus
outpatient setting); and by age, race, sex, and race/sex
subgroups. Age categories for incidence estimate standard-
ization included 67 to 69, 70 to 74, 75 to 79, and ≥80 years
of age. All analyses were performed using SAS version 9.4
(SAS Institute Inc.). Written informed consent was obtained
from participants, and all institutional review boards approved
the study.
Results
The 10 481 ARIC cohort members who met eligibility
requirements generally reflected the demographic distribution
in the original ARIC cohort at baseline. The majority were
female (58%) and white (76%), with black men (8%) as the
least represented group (Table 1). Mean comorbidity scores
were similar across race, sex, and race/sex strata. Mean
comorbidity score increased as the cohort aged from 2003 to
2012 (Table 1).
Age-Standardized Annual Prevalence and
Weighted Mean Annual Prevalence of PAD
Age-standardized annual and weighted mean annual esti-
mates of the prevalence of PAD across all study years (2003–
2012), overall and stratified by health care setting, are
provided in Table 2. The weighted mean annual PAD period
prevalence was 12.4% (95% CI 12.2–12.8%). Overall age-
standardized prevalence varied modestly from year to year,
ranging from 10.3% (95% CI 8.6–12.0%) to 13.5% (95% CI
12.4–14.6%).
Higher annual PAD period prevalence was identified in the
outpatient setting compared with the inpatient setting
(11.8% versus 1.6%) (Table 2). The majority of all unique
PAD claims (>70%) identified were from outpatient settings.
Prevalence of outpatient PAD claims ranged across years of
observation from 9.5% (95% CI 7.9–11.2%) in 2003 to 12.9%
(95% CI 11.9–14.0%) in 2012. By comparison, prevalence of
inpatient PAD ranged across years of observation from 1.4%
(95% CI 1.1–1.7%) in 2005 to 1.8% (95% CI 1.4–2.3%) in
2012.
Estimates of annual PAD period prevalence were further
stratified by demographic groups. Age-standardized annual
PAD period prevalence and mean annual prevalence were
consistently higher among those aged ≥75 years compared
with those aged 65 to 74 years (Figure 1). Weighted mean
annual PAD prevalence among those aged ≥75 years and 65
to 74 years was 16.8% and 8.4%, respectively. From 2003 to
2012, annual PAD prevalence in the age group ≥75 years
ranged from 12.5% (95% CI 9.0–15.9%) in 2003 to 18.5% (95%
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CI 17.1–20.0%) in 2012. Annual PAD prevalence among those
aged 65 to 74 years ranged from 8.0% (95% CI 7.2–8.8%) to
9.0% (95% CI 8.0–10.0%) over the same time frame.
Black participants had higher mean annual prevalence of
PAD compared with white participants (15.6% versus 11.4%)
and had higher annual prevalence of PAD across most years
of the observation period (Figure 2). From 2003 to 2012, PAD
prevalence among black participants ranged from 13.8% (95%
CI 10.4–17.2%) to 17.3% (95% CI 15.0–19.7%), whereas PAD
prevalence among white participants ranged from 9.0% (95%
CI 7.1–10.9%) to 12.8% (95% CI 11.6–14.0%). Regarding race/
sex stratification, black women had the highest weighted
mean annual PAD prevalence (16.9%), followed by black men
(13.2%), white men (12.1%), and white women (10.9%)
(Table S4).
Age-standardized prevalence of PAD did not differ by sex
alone in any year of observation (2003–2012). Overall,
women had higher prevalence of PAD, although confidence
intervals overlapped across many years of this study
(Table S5).
Age-Standardized Annual Incidence and Weighted
Mean Annual Incidence of PAD
Overall and age-standardized annual estimates of the inci-
dence of PAD across all observation years (2005–2012),
stratified by health care setting, are provided in Table 3. The
mean age-standardized PAD incidence rate across all obser-
vation years (2005–2012) was 26.8 per 1000 person-years
Table 1. ARIC Fee-for-Service Enrollees by Year and Demographic Groups, 2003–2012
2003
(n=7293)
2004
(n=7678)
2005
(n=7708)
2006
(n=7372)
2007
(n=7060)
2008
(n=6995)
2009
(n=6504)
2010
(n=6183)
2011
(n=5914)
2012
(n=5546)
Age, %, y
65–74 72 69 66 63 60 57 54 49 44 40
≥75 28 31 34 37 40 43 46 51 56 60
Sex, %
Female 57 57 58 57 58 58 59 60 60 61
Male 43 43 42 43 42 42 41 40 40 39
Race, %
Black 26 26 26 23 21 22 23 24 24 24
White 74 74 74 77 79 78 77 76 76 76
Race/sex, %
Black woman 17 17 18 15 14 14 15 16 16 16
Black man 9 9 9 8 7 7 8 8 8 8
White women 40 40 40 42 44 44 45 44 44 44
White man 34 34 33 35 35 34 32 32 32 32
Overall mean comorbidity
score* (SD)
1.7 (2.2) 1.8 (2.3) 1.9 (2.2) 1.9 (2.2) 2.1 (2.3) 2.1 (2.3) 2.3 (2.5) 2.4 (2.5) 2.5 (2.5) 2.6 (2.6)
Overall median comorbidity
score*
1 (0, 3) 1 (0, 3) 1 (0, 3) 1 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 3) 2 (0, 4) 2 (1, 4)
ARIC indicates atherosclerosis risk in communities.
*Klabunde adaptation15 of Charlson comorbidity index.
Table 2. Age-Standardized* Overall and Annual Prevalence of
Peripheral Artery Disease Claims Overall and by Health Care
Setting: The ARIC Cohort Study (2003–2012)
Prevalence, % (95% CI)
Overall Outpatient Setting Inpatient Setting
2003 10.3 (8.6–12.0) 9.5 (7.9–11.2) 1.5 (1.0–1.9)
2004 11.2 (10.0–12.4) 10.4 (9.3–11.6) 1.8 (1.3–2.3)
2005 11.4 (10.5–12.4) 10.8 (9.8–11.7) 1.4 (1.1–1.7)
2006 12.1 (11.1–13.0) 11.5 (10.6–12.4) 1.8 (1.4–2.1)
2007 12.3 (11.4–13.2) 11.5 (10.7–12.4) 1.4 (1.1–1.7)
2008 11.8 (10.9–12.6) 11.2 (10.4–12.0) 1.6 (1.3–1.9)
2009 12.6 (11.7–13.4) 12.0 (11.1–12.8) 1.4 (1.1–1.7)
2010 13.2 (12.3–14.1) 12.7 (11.8–13.5) 1.4 (1.1–1.7)
2011 13.1 (12.2–14.0) 12.7 (11.7–13.5) 1.6 (1.3–1.9)
2012 13.5 (12.4–14.6) 12.9 (11.9–14.0) 1.8 (1.4–2.3)
Weighted
mean
12.4 (12.2–12.8) 11.8 (11.5–12.1) 1.6 (1.5–1.7)
ARIC indicates atherosclerosis risk in communities.
*Standardized to reflect age distribution of 2005 Medicare population.
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(95% CI 25.1–28.6). The age-standardized incidence of PAD
remained relatively consistent across the study period (2005–
2012), ranging from 25.6 per 1000 person-years (95% CI
20.8–30.4) in 2007 to 30.3 per 1000 person-years (95% CI
24.9–35.7) in 2012 (Table 3).
The first PAD-related claim most commonly was found in
the outpatient setting (83%), at >5 times the incidence in the
inpatient setting (Table 3). Rates of PAD incidence in the
outpatient setting per 1000 person-years ranged from 20.0
(95% CI 15.2–24.8) to 26.0 (95% CI 21.0–30.9). Records of
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Figure 1. Age-standardized annual prevalence of peripheral artery disease (PAD) by age group. The ARIC (Atherosclerosis Risk in
Communities) study, 2003–2012. Estimates are standardized to the 2005 Medicare population.
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Figure 2. Age-standardized annual prevalence (percentage) of peripheral artery disease (PAD) by race group. The ARIC (Atherosclerosis Risk in
Communities) study, 2003–2012. Estimates are age-standardized to 2005 Medicare population.
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PAD-related hospitalizations were rare; for the years 2005 to
2012, the annual age-standardized incidence rates per
1000 person-years ranged from 3.2 (95% CI 1.5–4.8) in
2011 to 6.4 (95% CI 3.4–9.3) in 2005.
Annual estimates of PAD incidence were stratified by
demographic groups. Age-standardized annual PAD incidence
was different by age strata at all years examined except 2009
and 2012 (Figure 3). Incidence of PAD was higher among
those aged ≥75 years compared with 65 to 74 years. From
2005 to 2012, estimates of annual PAD incidence per
1000 person-years among those aged ≥75 years ranged from
31.6 (95% CI 24.1–39.2) in 2009 to 37.2 (95% CI 29.5–45.0)
in 2012. Estimates among those aged 65 to 74 years ranged
from 16.2 per 1000 person-years (95% CI 12.3–20.1) to 21.7
per 1000 person-years (95% CI 14.3–29.1) over the same
time period.
PAD incidence rates were different by race (Figure 4), with
higher mean annual (2005–2012) PAD incidence among black
participants (31.3 per 1000 person-years; 95% CI 27.3–35.4)
compared with white participants (25.4 per 1000 person-
years; 95% CI 23.5–27.3). Black participants had a higher
incidence rate of PAD than white participants across most
observation years, although annual differences were attenu-
ated due to low precision resulting from a small sample size
among black participants (Figure 4). Incidence rates of PAD
among black participants ranged from 28.4 per 1000 person-
years (95% CI 16.4–40.3) to 32.7 per 1000 person-years (95%
CI 21.3–44.1), whereas incidence of PAD among white
participants ranged from 23.2 per 1000 person-years (95%
CI 17.1–29.4) to 29.6 per 1000 person-years (95% CI
23.7–35.6).
The age-standardized annual incidence of PAD did not
differ by sex (Table S6). Mean annual incidence of PAD
(2005–2012) was higher among black men and black women
(31.8 and 30.9 per 1000 person-years, respectively) than
among white men and white women (25.5 and 25.3 per
1000 person-years, respectively), although confidence
Table 3. Age-Standardized* Overall and Annual Incidence of
Peripheral Artery Disease Claims Overall and by Health Care
Setting of Incident Claim: The ARIC Cohort Study (2005–2012)
Age-Standardized Rate, Per 1000 Person-Years (95% CI)*
Overall Outpatient Inpatient
2005 26.6 (20.7–32.6) 20.3 (15.1–25.4) 6.4 (3.4–9.3)
2006 25.8 (20.3–31.3) 20.0 (15.2–24.8) 5.8 (3.1–8.5)
2007 25.6 (20.8–30.4) 21.5 (17.2–25.9) 4.0 (2.0–6.1)
2008 26.0 (21.0–31.0) 21.2 (16.7–25.7) 4.8 (2.7–6.9)
2009 25.6 (20.9–30.3) 20.6 (16.4–24.8) 5.0 (2.9–7.1)
2010 29.3 (24.2–34.4) 25.9 (21.1–30.7) 3.4 (1.7–5.0)
2011 26.5 (21.7–31.4) 23.3 (18.8–27.9) 3.2 (1.5–4.8)
2012 30.3 (24.9–35.7) 26.0 (21.0–30.9) 4.3 (3.7–5.1)
Weighted
mean
26.8 (25.1–28.6) 22.4 (20.8–24.0) 4.4 (3.7–5.1)
ARIC indicates atherosclerosis risk in communities.
*Standardized to reflect age distribution of 2005 Medicare population.
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Figure 3. Age-standardized annual incidence (per 1000 person-years) of peripheral artery disease (PAD) by age group. The ARIC
(Atherosclerosis Risk in Communities) study, 2005–2012. Estimates are age-standardized to 2005 Medicare population; rates are per
1000 person-years.
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intervals overlapped in many years of observation. Small
sample sizes precluded annual assessment of PAD incidence
across race/sex groups (Figure S1).
Discussion
We found that the majority of all clinical PAD encounters
occurred in the outpatient setting among a biracial, probabil-
ity-based sample of 4 US communities, including men and
women aged ≥65 years with enrollment in a Medicare FFS
program. Studies that focus exclusively on hospitalized events
underreport burden and provide a perspective of PAD skewed
toward more severe manifestations occurring later in the
course of the disease. Black participants had higher preva-
lence of PAD than white participants, including both men and
women. Incidence of PAD was also higher among black
participants, although the relatively small proportion of black
participants in our study (24%) limited our ability to make
inferences in race- and race/sex- stratified analyses of PAD
incidence.
Although sources of administrative claims are increasingly
used to study PAD burden, methodological and source
population differences make it difficult to compare PAD
estimates across studies. In particular, it is well documented
that PAD prevalence increases with age16,20; however, prior
claims-based work did not report age-adjusted estimates of
PAD prevalence, limiting comparisons across populations with
differing age groups. A recent study using the MarketScan
database, for example, reported higher annual PAD preva-
lence among Medicare beneficiaries than the present study
(14–21% versus 10–14%)16; however, the population in the
MarketScan study was older and had more comorbidity.
Conversely, a study of a healthier group of managed care
enrollees found a lower prevalence of PAD (2%) than what was
observed in the present study.2 In the context of these other
studies, age-standardized estimates of PAD prevalence (over-
all 12.4%) in the present study are within the expected range,
given the estimates from younger and older populations.
Estimates of PAD incidence are rare in the literature and,
as with prevalence studies, are difficult to compare because
of differing study populations and inconsistency in the
definition of PAD. When using administrative claims data for
the estimation of disease incidence, the use of an appropriate
look-back period is important for the correct identification of
index events. Recent analyses suggest that for most chronic
diseases, a 2-year look-back period is necessary for the
exclusion of preexisting conditions.18 Studies that do not
include a sufficiently long look-back period have the potential
to reflect prevalent disease that is misclassified as incident
(up to 30%).18 Results of the current study, in which we used a
2-year look-back period, suggest that 2% to 3% (26.8 per
1000 person-years) of Medicare beneficiaries had an incident
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Figure 4. Age-standardized annual incidence of peripheral artery disease (PAD; per 1000 person-years), by race groups. The ARIC
(Atherosclerosis Risk in Communities) study, 2005–2012. Estimates are age-standardized to 2005 population; rates are per 1000 person-years.
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PAD occurrence within any particular observation year (2005–
2012). Although our incidence estimates are lower, they are
comparable to those in existing studies.16
Prior literature suggests differences in PAD burden by
race.21 Black participants were observed to have higher PAD
prevalence than white participants in the following studies:
NHANES (National Health and Nutrition Examination Survey),
SDPS (San Diego Population Study), MESA (Multi-Ethnic Study
of Atherosclerosis), and CHS (Cardiovascular Health
Study).6,7,22,23 In the current study, we found that the mean
annual prevalence and incidence of PAD was higher among
black than white participants, which confirms these prior
observations. The current study adds the finding that PAD
burden was higher among black participants despite known
access to care issue in this population. This study further adds
to estimates of PAD burden by providing race/sex analyses. We
observed that black women consistently had the highest PAD
prevalence, whereas white women had the lowest PAD
prevalence across all years of observation (2003–2012)
(Table S4). Black men had the highest mean PAD incidence
followed by black women (Figure S1). Findings from this study
suggest black persons aged ≥65 years have a higher burden of
PAD and thus could benefit from prevention efforts targeting
individuals well before they become age-eligible for Medicare.
The American Heart Association (AHA) recently identified
sex-specific estimates of PAD, particularly for women, as a
knowledge gap in the literature. The present study answers a
challenge from the AHA to produce age-standardized, sex-
specific estimates.24 Men in this study had nearly identical
age-standardized PAD estimates compared with women
overall (mean annual prevalence 12.4% versus 12.5%; mean
annual incidence 26.9 versus 26.8 per 1000 person-years)
and at most years of observation. The minimal differences
observed in PAD burden by sex were in accordance with the
limited literature regarding sex-specific estimates of PAD
prevalence and incidence.10,20 We acknowledge the potential
sex-based differences in evaluation of PAD and agree with
others that these differing practices (1) likely have caused
historical underestimation of PAD burden among women and
(2) led clinicians to identify male sex as a PAD risk factor.22
Although we are unable to verify this type of sex bias in our
study, our data add to a growing body of research suggesting
that the burden of PAD is at least similar for women and men.
Finally, despite the known coexistence of PAD with other
major circulatory system disorders,25,26 health professional
and public awareness of PAD is low in comparison to the
awareness of diseases such as stroke, coronary heart disease,
heart failure, and atrial fibrillation.9,27 Interestingly, PAD
prevalence estimates in this study are similar to recent
assessments of prevalence of stroke (5–6% in those aged
60–79 years; 14–16% in those aged ≥80 years) and coronary
heart disease (10–20% in those aged 60–79 years, 19–32% in
those aged ≥80 years).21 Still, although these estimates
suggest a significant PAD burden in this population, clinicians
often do not evaluate for the presence of PAD. Furthermore,
up to 50% of persons with PAD are asymptomatic and might
not be actively seeking PAD-related care.9 Our claims-based
estimates, which capture PAD in a clinical setting and thus
would be unlikely to include asymptomatic PAD, are likely an
underestimation of the prevalence and incidence of PAD in
the Medicare-aged population.
Strengths and Limitations
The most important strength of this study is the inclusion of
outpatient in addition to inpatient clinical encounters in the
assessment of prevalent and incident PAD. Prior studies have
provided limited information on the burden of PAD stratified
by the setting of health care delivery (inpatient versus
outpatient). Although a study by Hirsch et al found that
inpatient visits represent up to 90% of PAD-related costs,28
>70% of all PAD claims in the current study were found in the
outpatient records. In addition, >80% of all incident PAD
events were found to have occurred in the outpatient setting.
These estimates are age-standardized, and look-back periods
for incidence are in accordance with recent recommenda-
tions, providing a further strength of this study.
Because this study was based on inpatient and outpatient
care among CMS Medicare enrollees in FFS programs, our
estimates are not generalizable to Medicare beneficiaries
enrolled in Medicare Advantage, who have been reported to
be healthier than those in FFS.29 Our estimates reflect cohort
survivors, and we did not attempt to quantify PAD prior to
enrollment in FFS in 2003. Administrative claims data reflect
billing practices; therefore, diagnostic coding found in claims
data is not always accurate in relation to documented
diagnoses or procedures. Codes selected were not indepen-
dently validated, which could lead to misclassification of PAD
occurrence. Upcoding might increase billing by as much as
15%,30 and illness severity is not readily obtainable from
claims data.
Conclusions
Findings from this study suggest that PAD is an important
circulatory system disorder similar in prevalence to stroke and
coronary heart disease. This study addresses an important
gap in the existing literature by providing accurate estimates
of PAD in the outpatient setting, where the majority of PAD
burden was found. PAD estimates stratified by race corrob-
orated other population-based studies that reported a higher
burden among black compared with white participants; future
work should focus on identifying effective prevention of PAD
and its sequelae in this group.
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Table S1. Exclusion criteria to arrive at final dataset. The ARIC Study, 2003-2012 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Total in dataset 9948 10380 10821 11250 11563 11657 11440 11085 10718 10355 
Exclusions for  
HMO 2013 2140 2640 3478 4200 4495 4863 4856 4759 4670 
race 39 44 44 45 41 40 41 41 40 37 
age <65 603 518 429 355 262 127 32 5 5 2 
Final Enrollees 7293 7678 7708 7372 7060 6995 6504 6183 5914 5546 
 ARIC= Atherosclerosis Risk in Communities 
 
  
Table S2. International Classification of Diseases, Ninth Revision (ICD-9-CM), Current Procedural Terminology, 4th edition (CPT-4), 
Healthcare Common Procedure Coding System (HCPCS), and Federally Qualified Healthcare Revenue Center (FQHC) codes used to 
identify peripheral artery disease in claims. 
Code Type Codes 
ICD-9-CM 249.70, 249.71, 250.70, 250.71, 250.72, 250.73, 440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 440.30, 440.31, 440.32, 440.4, 440.8, 
440.9, 443.1, 443.22, 443.81, 443.89, 443.9, 444.22, 444.81, 445.02 
 
* 38.08, 38.16,, 38.18, 38.38, 38.48, 39.25, 39.29, 39.49, 39.50, 39.56, 39.57, 39.58, 39.90, 84.10, 84.12, 84.13, 84.14, 84.15 , 84.16, 
84.17, 84.18, 84.3, 84.91 
HCPCS/CPT-4 27295, 27590, 27591, 27592, 27594, 27596, 27598,27599,27880, 27881, 27882, 27888, 27889, 28800, 28805, 28810, 28820, 28825, 
35221, 35226, 35256, 35286, 35302, 35303, 35304, 35305, 35306, 35331, 35351, 35355, 35361, 35363, 35371, 35372, 35381, 35452, 
35454, 35456, 35459, 35470, 35472, 35473, 35474, 35480, 35481, 35482, 35483, 35485, 35490, 35491, 35492, 35493, 35495, 35500,  
35521, 35533, 35537, 35538, 35539, 35540, 35541, 35546, 35548, 35549, 35551, 35556, 35558, 35563, 35565, 35566, 35583, 35585, 
35587, 35621, 35623, 35646, 35647, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 35671, 35681, 35682, 35700, 35875, 35876,  
35879, 35881, 35883, 35884, 35903 
 
* 35683, 35686, 35571, 72191, 72198, 73706, 73725, 74175, 74185, 75630, 75631, 75635, 75710, 75711, 75712, 75716, 75717, 75718,  
93922, 93924, 93925, 93926, 93978, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99216,  99241, 99242, 
99243, 99244, 99245, 99385, 99386, 99387, 99395, 99396, 99397 
 
Revenue Center Codes *0320,0321,0322,0323,0324,0329,0360,0361,0370,0371,0372,0379,0402,0490,0499,0510,0517,0519,0520,0521,0610,0616,0710,0760, 
0761,0762,0769,0921 
* Must be accompanied with a PAD-related ICD-9-CM code 
ICD-9-CM Diagnosis Codes for PAD: Definitions 
Description Code 
Atherosclerosis: 
of native arteries of the extremities  
of bypass graft of the extremities  
of other specified arteries  
 
440.2x 
440.3x 
440.8x 
Generalized and unspecified atherosclerosis:  
arteriosclerotic vascular disease NOS 
Peripheral vascular disease, unspecified  
 
440.9× 
443.9x 
Chronic total occlusion of artery of the extremities 440.4 
Arterial embolism and thrombosis of lower extremity 444.22 
Embolism and thrombosis of iliac artery 444.81 
Atheroembolism of lower extremity 445.02 
Diabetes with peripheral circulatory disorders, Type II or unspecified type, not 
stated as uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), not stated 
as uncontrolled 
Diabetes with peripheral circulatory disorders, Type II or unspecified type, 
uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), 
uncontrolled 
250.70 
 
 
250.71 
 
250.72 
250.73 
 ICD-9-CM Surgical/Intervention Procedure Codes for PAD: Definitions 
Description Code 
Amputation of lower limb  
Amputation not otherwise specified  
Aorta-iliac-femoral bypass  
Other (peripheral) vascular shunt or bypass  
Incision of lower limb arteries  
Endarterectomy, abdominal arteries 
Endarterectomy, lower limb arteries  
Resection of vessel with anastomosis, lower limb arteries   
Resection of vessel with replacement, lower limb arteries  
Other excision of vessels, lower limb arteries  
Other revision of vascular procedure  
Angioplasty or atherectomy of other non-coronary vessel(s) Insertion of non-drug-
eluting peripheral vessel stent(s)  
Repair of blood vessel with tissue patch graft  
Repair of blood vessel with synthetic patch graft  
Repair of blood vessel with unspecified type of patch graft 
84.1x 
84.91  
39.25 
39.29 
38.08 
38.16 
38.18 
38.38 
38.48 
38.68 
39.49 
39.50 
39.90 
39.56 
39.57 
39.58 
 
CPT-4 codes for PAD-related surgical or intervention procedures: Definitions 
Description Code 
Repair blood vessel lower extremity; 
direct  
with vein graft  
with graft other than vein  
 
35226 
35256 
35286 
Thromboendarterectomy, including patch graft, if performed; superficial femoral artery  
popliteal artery  
tibioperoneal trunk artery  
tibial or peroneal artery, initial vessel  
each additional tibial or peroneal artery  
 
35302 
35303 
35304 
35305 
35306 
Thromboendarterectomy, with or without patch graft;  
abdominal aorta (35331); 
 iliac (35351);  
iliofemoral (35355);  
combined aortoiliac (35361);  
combined aortoiliofemoral (35363);  
common femoral (35371);  
deep (profunda) femoral (35372);  
femoral and/or popliteal, and/or tibioperoneal (35381) 
 
35331 
35351 
35355 
35361 
35363 
35371 
35372 
35381 
In-situ vein bypass;  
aortofemoral-popliteal (only femoral-popliteal portion in-situ)  
 
femoral-popliteal  
femoral-anterior tibial, posterior tibial, or peroneal artery  
popliteal-tibial, peroneal  
 
35582 
35583 
35585 
35587 
Bypass graft, with vein;  
axillary-femoral  
axillary-femoral-femoral  
aortoiliac  
aortobi-iliac  
aortofemoral  
aortobifemoral  
aortoiliac or bi-iliac  
aortofemoral or bifemoral  
aortoiliofemoral, unilateral  
aortoiliofemoral, bilateral  
aortofemoral-popliteal  
femoral-popliteal  
femoral-femoral 
 ilioiliac  
 iliofemoral  
femoral-anterior tibial, posterior tibial, peroneal artery or other distal vessels  
popliteal-tibial,-peroneal artery or other distal vessels  
 
35521 
35533 
35537 
35538 
35539 
35540 
35541 
35546 
35548 
35549 
35551 
35556 
35558 
35563 
35565 
35566 
35571 
Percutaneous:  
aortic  
iliac  
femoral-popliteal  
tibioperoneal trunk and branches 
 
35491 
35492 
35493 
35495 
Transluminal peripheral atherectomy, Open:  
aortic  
iliac  
femoral-popliteal  
tibioperoneal trunk and branches 
 
35481 
35482 
35483 
35485 
Transluminal balloon angioplasty, percutaneous;  
tibioperoneal trunk and branches, each vessel  
aortic  
iliac  
femoral-popliteal  
 
35470 
35472 
35473 
35474 
Transluminal balloon angioplasty, open;  
aortic (35452);  
iliac (35454);  
femoral-popliteal (35456);  
tibioperoneal trunk and branches (35459);  
 
35452 
35454 
35456 
35459 
Bypass graft, with other than vein;  
axillary-femoral  
axillary-popliteal or –tibial  
aortoiliac  
aortobi-iliac  
aortoiliac or bi-iliac  
aortofemoral or bifemoral 
aortofemoral  
aortofemoral-popliteal  
axillary-femoral-femoral  
femoral-popliteal  
femoral-femoral  
ilioiliac  
iliofemoral  
femoral-anterior tibial, posterior tibial, or peroneal artery  
popliteal-tibial or -peroneal artery  
 
35621 
35623 
35637 
35638 
35641 
35646 
35647 
35651 
35654 
35656 
35661 
35663 
35665 
35666 
35671 
Exploration, reoperation, femoral-popliteal or femoral (popliteal) -anterior tibial, 
posterior tibial, peroneal artery or other distal vessels, more than one month after 
original operation (List separately in addition to code for primary procedure)  
 
 
35700 
Exploration (not followed by surgical repair), with or without lysis of artery;  
femoral artery  
popliteal artery  
  
35721 
35741 
Thrombectomy of arterial or venous graft, with revision of arterial or venous graft 35876 
Revision, lower extremity arterial bypass, without thrombectomy, open;  
with vein patch angioplasty  
with segmental vein interposition 
 
35879 
35881 
Revision, femoral anastomosis of synthetic arterial bypass graft in groin, open;  
with non autogenous patch graft (e.g., Dacron, ePTFE, bovine pericardium)  
with autogenous vein patch graft  
 
35883 
35884 
Primary percutaneous transluminal mechanical thrombectomy, noncoronary, arterial or 
arterial bypass graft, including fluoroscopic guidance and intra procedural 
pharmacological thrombolytic injection(s);  
initial vessel  
second and all subsequent vessel(s) within the same vascular family (List separately in 
addition to code for primary mechanical thrombectomy procedure)  
 
 
 
37184 
 
37185 
Secondary percutaneous transluminal thrombectomy (e.g., non primary mechanical, 
snare basket, suction technique), noncoronary, arterial or arterial bypass graft, 
including fluoroscopic guidance and intra procedural pharmacological thrombolytic 
injections, provided in conjunction with another percutaneous intervention other than 
primary mechanical thrombectomy (List separately in addition to code for primary 
procedure)  
 
 
 
 
37186 
Transcatheter placement of an intravascular stent(s), (except coronary, carotid, and 
vertebral vessel), percutaneous; 
initial vessel (37205) 
each additional vessel (List separately in addition to code for primary procedure) 
 
 
37205 
37206 
Transcatheter placement of an intravascular stent(s), (except coronary, carotid, and 
vertebral vessel), open; 
each additional vessel (List separately in addition to code for primary procedure)  
 
 
37208 
Disarticulation;  
of hip   
at knee  
of ankle   
 
27295 
27598 
27889 
Amputation, thigh, through femur, any level   
immediate fitting technique including first cast  
open, circular (guillotine)  
leg, through tibia and fibula  
with immediate fitting technique including application of first cast  
open, circular (guillotine)  
ankle, through malleoli of tibia and fibula (e.g., Syme, Pirogoff type procedures), with 
plastic closure and resection of nerves  
foot; midtarsal (e.g., Chopart type procedure)  
transmetatarsal  
27590 
27591 
27592 
27880 
27881 
27882 
 
27888 
28800 
28805 
 
CPT-4 codes for PAD-related diagnostic procedures: Definitions 
Description Code 
Aortography:   
abdominal plus bilateral iliofemoral lower extremity, catheter, by serialography, radiological  
complete procedure  
 
 
75630 
75631 
Angiography, extremity, unilateral, radiological supervision and interpretation  
complete procedure  
bilateral; by serialography, complete procedure  
radiological  
without serialography; complete procedure 
by serialography, complete procedure  
75710 
75711 
75712 
75716 
75717 
75718 
Arterial duplex of the lower extremities,  
unilateral  
bilateral  
aorta  
 
93925 
93926 
93978 
CT Angiogram Abdomen with & w/o contrast  
Pelvis  
Lower Extremity  
abdominal aorta and bilateral iliofemoral lower extremity runoff  
74175 
72191 
73706 
75635 
MRA abdomen images from the diaphragm to the umbilicus or iliac crest 74185 
Pelvis  
 
72198 
Lower extremity w/ or w/o contrast  73725 
Non-invasive physiologic studies of lower extremity arteries, single level, bilateral  
at rest and following treadmill stress testing, complete bilateral study 
93922 
93924 
 
Other PAD-related codes: Definitions 
Description Code 
Chronic total occlusion of artery of the extremities 440.4 
Arterial embolism and thrombosis of lower extremity 444.22 
Embolism and thrombosis of iliac artery 444.81 
Atheroembolism of lower extremity 445.02 
Diabetes with peripheral circulatory disorders, Type II or unspecified type, not stated as 
uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), not stated as 
uncontrolled 
Diabetes with peripheral circulatory disorders, Type II or unspecified type, uncontrolled 
Diabetes with peripheral circulatory disorders, Type I (Juvenile type), uncontrolled 
250.70 
 
 
250.71 
 
250.72 
250.73 
Endarterectomy, abdominal arteries 38.16 
 
  
Table S3. Sensitivity analysis comparing requiring two outpatient claims versus 
one outpatient claim to identify prevalence of PAD in the outpatient setting. The ARIC Study, 2003-2012 
 
Outpatient PAD Prevalence+ % 
(95% CI) 
Outpatient PAD Prevalence* % 
(95% CI) 
2003 4.0 (3.1, 4.9) 9.5 (7.9, 11.2) 
2004 6.7 (5.7, 7.6) 10.4 (9.3, 11.6) 
2005 6.7 (5.9, 7.4) 10.8 (9.8, 11.7) 
2006 7.2 (6.5, 7.9) 11.5 (10.6, 12.4) 
2007 7.3 (6.6, 7.9) 11.5 (10.7, 12.4) 
2008 7.6 (6.9, 8.2) 11.2 (10.4, 12.0) 
2009 8.0 (7.4, 8.8) 12.0 (11.1, 12.8) 
2010 8.7 (8.0, 9.5) 12.7 (11.8, 13.5) 
2011 9.5 (8.7, 10.3) 12.7 (11.7, 13.5) 
2012 10.0 (9.1, 10.9) 12.9 (11.9, 14.0) 
Weighted Mean 7.9 (7.7, 8.2) 11.8 (11.5, 12.1) 
 + Requires two outpatient claims in a year for prevalence estimates; * Requires one outpatient claim for prevalence estimates; ARIC= Atherosclerosis Risk in 
Communities; Estimates are standardized to 2005 Medicare population 
  
Table S4. *Age-standardized annual prevalence of peripheral artery disease in the inpatient and outpatient setting by race-
sex groups. The ARIC Study, 2003-2012 
 White Males White Females Black Males Black Females 
 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
Prevalence 
% 95% CI 
2003 9.6 7.4, 11.8 8.8 5.6, 12.0 10.1 6.6, 13.6 16.2 10.8, 21.6 
2004 10.9 9.1, 12.8 9.4 7.4, 11.3 10.5 7.8, 13.3 16.6 12.7, 20.4 
2005 11.2 9.7, 12.8 9.4 7.9, 10.8 13.5 10.5, 16.4 15.4 12.3, 18.4 
2006 12.6 11.0, 14.1 9.2 7.9, 10.5 14.1 10.9, 17.3 16.7 13.7, 19.8 
2007 12.0 10.6, 13.4 10.2 8.9, 11.4 15.0 11.5, 18.5 18.7 15.5, 21.9 
2008 11.7 10.3, 13.1 10.0 8.8, 11.2 15.3 11.8, 18.8 15.0 12.3, 17.7 
2009 12.2 10.7, 13.7 10.9 9.6, 12.1 14.6 11.3, 17.9 16.5 13.8, 19.1 
2010 13.0 11.4, 14.6 11.7 10.4, 13.0 12.9 9.8, 16.1 17.8 15.1, 20.6 
2011 12.1 10.5, 13.8 12.4 11.0, 13.7 11.6 8.4, 14.8 17.2 14.4, 19.9 
2012 12.3 10.4, 14.2 13.3 11.7, 14.8 13.6 9.3, 17.9 16.2 13.1, 19.2 
Weighted 
Mean 12.1 11.6, 12.5 10.9 10.4, 11.3 13.2 12.2, 14.2 16.9 16.0, 17.8 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare population 
 
 Table S5. Age-standardized annual prevalence of peripheral artery disease in the 
inpatient and outpatient setting by sex. The ARIC Study, 2003-2012 
 Male Female 
 Prevalence % 95% CI Prevalence % 95% CI 
2003 9.7 7.8, 11.7 11.1 8.2, 13.9 
2004 10.8 9.2, 11.7 11.6 9.8, 13.4 
2005 11.8 10.4, 13.2  11.1 9.8, 12.5 
2006 13.0 11.6, 14.4 11.1 10.9, 12.3 
2007 12.6 11.3, 13.9 12.1 10.1, 13.3 
2008 12.4 11.1, 13.7 11.2 11.2, 13.6 
2009 12.7 11.4, 14.1 12.4 12.1, 14.6 
2010 13.1 11.7, 14.5 13.4 12.5, 15.0 
2011 12.2 10.7, 13.6 13.8 12.5, 15.0 
2012 12.8 11.0, 14.5 14.2 12.8, 15.6 
Weighted Mean 12.4 12.0, 12.8 12.6 12.1, 12.9 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare 
population 
 
Table S6. Age-standardized annual incidence of peripheral artery disease in the inpatient and 
outpatient setting by sex. The ARIC Study, 2005-2012 
  Male Female 
  Events 
Person-
time 
Age-standardized 
rate Events Person-time 
Age-standardized 
rate 
2005 66 2667 31.5 (22.0, 41.0) 72 3702 22.1 (15.0, 29.2) 
2006 57 2530 31.1 (22.0, 40.1) 63 3512 20.5 (14.2, 26.8) 
2007 64 2391 28.7 (21.1, 36.3) 70 3382 23.4 (17.3, 29.5) 
2008 51 2319 25.2 (18.0, 32.4) 70 3352 26.6 (19.7, 33.5) 
2009 57 2096 28.0 (20.6, 35.4) 66 3106 24.2 (18.0, 30.5) 
2010 50 1949 26.2 (18.9, 33.5) 84 2944 31.6 (24.6, 38.7) 
2011 41 1817 23.2 (16.0, 30.4) 76 2786 29.0 (22.4, 35.7) 
2012 48 1655 27.4 (19.2, 35.6) 82 2561 32.8 (25.5, 40.1) 
Weighted Mean 434 17423 26.9 (24.3, 29.5) 583 25346 26.8 (24.5, 29.2) 
ARIC= Atherosclerosis Risk in Communities; Estimates are standardized to 2005 Medicare 
population 
  
Figure S1. Age-standardized annual incidence of peripheral artery disease in the inpatient and 
outpatient setting among four race/sex groups. The ARIC Study, 2005-2012 
ARIC= Atherosclerosis Risk in Communities; Estimates are age-standardized to 2005 Medicare 
population rates are per 1000 person-years 
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